Schrödinger, Inc. (NASDAQ:SDGR) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET

Company Participants

Jaren Madden - Senior Vice President, Investor Relations and Corporate Affairs

Ramy Farid - Chief Executive Officer

Geoff Porges - Chief Financial Officer

Karen Akinsanya - President of R&D, Therapeutics

Conference Call Participants

Do Kim - Piper Sandler

David Lebowitz - Citi

Gary Nachman - BMO Capital Markets

Wolf Chanoff - Bank of America

Operator

Thank you for standing by. Welcome to Schrödinger's Conference Call to review Fourth Quarter and Full Year 2022 Financial Results. My name is Liz, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions]

Please be advised that this call is being recorded at the company's request. I would now like to introduce your host for today's conference is Ms. Jaren Madden, Senior Vice President of Investor Relations and Corporate Affairs. Please go ahead.

Jaren Madden

Thank you, and good afternoon, everyone. Welcome to today's call during which we will provide an update on the company and review our fourth quarter and full year 2022 financial results. Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at schrödinger.com.

Here with me on our call today are Ramy Farid, Chief Executive Officer; Geoff Porges, Chief Financial Officer; and Karen Akinsanya, President of R&D, Therapeutics. Following our prepared remarks, we will open the call for Q&A.

I'd like to remind you that during today's call, management will make statements related to our business that are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our outlook for the full year 2023 and for the first quarter ending March 31, 2023, our strategic plans to accelerate the growth of our software business and advance our collaborative and proprietary drug discovery programs, the timing of potential IND submissions and the initiation of clinical trials for our proprietary drug discovery programs, the clinical potential and favorable properties of our compounds, our expectations related to the use of cash resources, as well as our future operating expenses.

These forward-looking statements reflect our views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made.